New weapon in fight against childhood cancer: antibody added to chemo
NCT ID NCT01857934
Summary
This study tested a new antibody drug (hu14.18K322A) given alongside standard chemotherapy for children with advanced, high-risk neuroblastoma. The goal was to see if adding this antibody, which targets cancer cells, improves treatment response and survival. The trial involved 153 children under 19 years old who were newly diagnosed and had not received prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.